NeuroXT earns FDA clearance for AI brain scan analyzer for Alzheimer’s
NeuroXT Inc announced that NEXT-Cue, its AI-based Software as a Medical Device supporting prognostic assessment in patients with mild cognitive impairment, has received 510(k) clearance from the U.S. Food and Drug Administration as a Class II medical device. NEXT-Cue integrates brain MRI images, dem
<p>NeuroXT Inc announced that NEXT-Cue, its AI-based Software as a Medical Device supporting prognostic assessment in patients with mild cognitive impairment, has received 510(k) clearance from the U.S. Food and Drug Administration as a Class II medical device. NEXT-Cue integrates brain MRI images, dem</p>